创模生物科技(北京)有限公司

CN / En

NEWS

Introduction to the InnoModels Biotechnology Bowel Disease (IBD) Modeling Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-09 11:20
  • Views:

(Summary description)Inflammatory Bowel Disease (IBD) is a group of non-specific chronic inflammatory diseases of the colon or gastrointestinal tract of unknown etiology, which was once called "green cancer" because of its easy recurrence and incurable nature.1 The two main types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). IBD consists of two main types: Ulcerative Colitis (UC) and Crohn's Disease (CD), which are characterized by a variety of clinical manifestations and complex treatment. In order to study the pathogenesis of IBD and develop effective therapeutic drugs, the InnoModels Biotechnology platform has constructed a series of animal models of inflammatory bowel disease that highly mimic the characteristics of human diseases.

Introduction to the InnoModels Biotechnology Bowel Disease (IBD) Modeling Platform

(Summary description)Inflammatory Bowel Disease (IBD) is a group of non-specific chronic inflammatory diseases of the colon or gastrointestinal tract of unknown etiology, which was once called "green cancer" because of its easy recurrence and incurable nature.1 The two main types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). IBD consists of two main types: Ulcerative Colitis (UC) and Crohn's Disease (CD), which are characterized by a variety of clinical manifestations and complex treatment. In order to study the pathogenesis of IBD and develop effective therapeutic drugs, the InnoModels Biotechnology platform has constructed a series of animal models of inflammatory bowel disease that highly mimic the characteristics of human diseases.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-09 11:20
  • Views:
Information

Introduction.
Inflammatory Bowel Disease (IBD) is a group of non-specific chronic inflammatory diseases of the colon or gastrointestinal tract of unknown etiology, which was once called "green cancer" because of its easy recurrence and incurable nature.1 The two main types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). IBD consists of two main types: Ulcerative Colitis (UC) and Crohn's Disease (CD), which are characterized by a variety of clinical manifestations and complex treatment. In order to study the pathogenesis of IBD and develop effective therapeutic drugs, the InnoModels Biotechnology platform has constructed a series of animal models of inflammatory bowel disease that highly mimic the characteristics of human diseases.
Platform Overview
The InnoModels Inflammatory Bowel Disease (IBD) platform is a comprehensive platform that integrates the research and development of innovative animal models, production and supply, and experimental services. Relying on advanced gene editing technology and standardized animal breeding management, the platform has established a variety of high-quality IBD animal models, which are widely used in the fields of disease mechanism, drug development and efficacy evaluation.
Introduction of main models
1. DSS-induced mouse IBD model
Dextran Sulfate Sodium Salt (DSS)-induced mouse IBD model is one of the most widely used chemical induced models. By dissolving DSS in drinking water, acute ulcerative enteritis or chronic colitis is induced, destroying the intestinal epithelial cells in mice, ultimately leading to disruption of the integrity of the mucosal barrier. This model is extremely similar to human ulcerative colitis in terms of clinical symptoms and pathological features, making it an ideal model for studying the pathogenesis of IBD and evaluating drug efficacy.
Model characteristics:
- Symptomatic manifestations: the animals showed obvious weight loss, loose stools, blood in the stool, and granulocyte infiltration.
- Pathological features: damage to intestinal epithelial cells, disruption of the integrity of the intestinal mucosal layer, and massive infiltration of inflammatory cells.
- Wide application: It can be used to evaluate the therapeutic effect of various drugs on IBD, such as Cyclosporin A (CsA).
2. TNBS-induced IBD model in rats
A mixture of 2,4,6-trinitrobenzene sulfonic acid (TNBS) and ethanol is commonly used to induce acute ulcerative colitis. Ethanol firstly destroys the intestinal mucosal barrier, and TNBS enters the colonic mucosal tissues and binds to proteins to form alloantigens, activates macrophages, releases a variety of pro-inflammatory factors, and further damages the intestinal mucosal barrier. The model is simple to operate, rapid modeling, and can simulate the acute and chronic dynamic process of ulcerative colitis.

 


Model characteristics:
- Symptomatic manifestations: weight loss, congestion and edema of the colonic mucosa, thickening of the muscularis propria, multiple ulcers, disappearance of glands and cupped cells, and infiltration of immune cells.
- Pathological features: in addition to the typical pathological manifestations of ulcerative colitis, submucosal hyperplasia of small blood vessels, connective tissue hyperplasia accompanied by fibrosis can also be seen.
- Application: It is suitable for the research of IBD etiology, pathogenesis and development of new drugs for treatment.
Platform Advantages
1. High-quality models
The InnoModels Biotechnology platform ensures the high quality and consistency of IBD models through rigorous gene editing technology and standardized animal husbandry management. These models can highly simulate human disease characteristics, providing a reliable experimental basis for scientific research and drug development.
2. Diversified Services
The platform provides one-stop solutions from model construction, feeding management to experimental services. Customers can choose suitable models for disease mechanism research or drug efficacy evaluation according to their own needs. Meanwhile, the platform also provides professional technical support and data analysis services to ensure the accuracy and reliability of the experimental results.
3. International Standard
All animals on the InnoModels Biotechnology platform are kept in AAALAC-accredited animal facilities and are evaluated for in vivo pharmacodynamics with reference to GLP management standards. This ensures the international recognition and comparability of the experimental results, providing strong support for global scientific collaboration and drug development.
Conclusion
The InnoModels Bioinflammatory Bowel Disease Model Platform is a comprehensive platform that combines innovation, efficiency and standardization. By constructing high-quality IBD animal models, the platform provides strong support for disease mechanism research and drug development. In the future, the platform will play an even more important role in the global biomedical field with the continuous advancement of technology and the expansion of applications.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司